Biomarkers

Alzheimers Dement. 2024 Dec;20 Suppl 2(Suppl 2):e088485. doi: 10.1002/alz.088485.

Abstract

Background: Primary Progressive Aphasia (PPA) is a clinical and symptomatic concept due to neurodegenerative diseases which language symptom was dominant from early clinical stage. PPA is categorized into 3 subtypes such as Progressive non-fluent aphasia (PNFA), Semantic dementia (SD), and logopenic progressive aphasia (LPA). In this study, we compared the differences of PPA subtypes depend on amyloid PET results.

Method: We recruited PPA patients who underwent standard aphasia test (SLTA) as Japanese aphasia test, cerebrospinal fluid AD biomarker, and amyloid PET. We divided into Amyloid PET positive (A(+) PPA) and negative (A(-) PPA) group. then we compared the characterization of SLTA results and CSF biomarker between two groups.

Result: A total of 15 patients were included. There were 7 patients in A (+) PPA groups (2 males and 5 females, age: 65.3±8.3 years), and 8 patients in A (-) PPA group (6 males and 2 females, age: 66.6±11.2 years). Regarding cerebrospinal fluid AD biomarkers, a significant decrease in Aβ42/40 (p < 0.01) and significant elevation in P-tau (p<0.01) was observed in the A (+) PPA group compared to the A (-) PPA group. In SLTA, the A (+) PPA had LPA: 57% and transcortical sensory aphasia: 29%. on the other hand, A (-) PPA group had PNFA: 38% and SD: 50%.

Conclusion: This study showed there is the possibility of SLTA may be useful to predict AD pathology in patients with PPA.

MeSH terms

  • Aged
  • Amyloid beta-Peptides* / cerebrospinal fluid
  • Aphasia, Primary Progressive* / diagnosis
  • Biomarkers* / cerebrospinal fluid
  • Brain / diagnostic imaging
  • Brain / pathology
  • Female
  • Humans
  • Language Tests
  • Male
  • Middle Aged
  • Peptide Fragments / cerebrospinal fluid
  • Positron-Emission Tomography*
  • tau Proteins* / cerebrospinal fluid

Substances

  • Biomarkers
  • Amyloid beta-Peptides
  • tau Proteins
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • amyloid beta-protein (1-40)